Koru Medical inks agreement with biopharma company on Freedom Infusion System
By HME News Staff
Updated 10:35 AM CDT, Thu August 3, 2023
MAHWAH, N.J. – Koru Medical Systems, a medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, has announced an agreement with a biopharmaceutical company to validate its Freedom Infusion System for use for use with the company’s drug. The company is expected to begin Phase III studies by the end of 2023 for treatment of a rare genetic disease with global prevalence of roughly 10,000 that currently has no pharmaceutical treatments. "Adding a late-stage pharmaceutical collaboration is a major milestone for our novel therapies business as we continue to progress our relationships to help drive greater knowledge and adoption around the benefits of subcutaneous drug delivery for patients in the home,” said Linda Tharby, Koru Medical’s president and CEO. “We are excited to partner with this rare disease biopharmaceutical company to bring a therapy to an area of significant unmet need where patients have few options today."
Comments